<DOC>
	<DOCNO>NCT02101879</DOCNO>
	<brief_summary>Approximately 15-25 % breast cancer human epidermal growth factor receptor 2 ( HER2 ) positive well know HER2 overexpression associate aggressive phenotype poor prognosis resistance certain chemotherapeutic agent . Trastuzumab administration adjuvant metastatic HER2 positive breast cancer associate symptomatic asymptomatic cardiotoxicity . The incidence trastuzumab-mediated cardiotoxicity 27 % antracycline combination 13 % administer paclitaxel . Pertuzumab , recombinant humanize monoclonal antibody bind HER2 dimerization domain , prevents dimerization HER2 HER receptor ( HER3 , HER1 , HER4 ) especially HER3 . Blocking HER2-HER3 dimerization postulate clinically relevant action pertuzumab effectively block her2-mediated cell signal . Pertuzumab indicate combination trastuzumab docetaxel treatment patient HER2-positive metastatic breast cancer receive prior anti-HER2 therapy chemotherapy metastatic disease . Treatment breast cancer pertuzumab plus trastuzumab plus docetaxel first line treatment disease progression might complicate cardiotoxicity 14.5 % Patients . Cardinale et al show troponin I ( TNI ) positive identifies trastuzumab-treated patient risk cardiotoxicity unlikely recover cardiac dysfunction despite HF therapy . There little data reversibility identification patient risk cardiotoxicity pertuzumab plus trastuzumab plus docetaxel regimen recover cardiac dysfunction , information crucial . The usefulness troponin I ( TNI ) Brain natriuretic peptide ( BNP ) identification patient risk PT cardiotoxicity prediction LVEF recovery never investigate . base background , study aim evaluate cardiotoxicity pertuzumab plus trastuzumab plus docetaxel regimen application troponin I ( TNI ) Brain natriuretic peptide ( BNP ) setting .</brief_summary>
	<brief_title>Cardiotoxicity Metastatic Her 2 Positive Patients Treated With Trastuzumab , Pertuzumab Taxanes</brief_title>
	<detailed_description>Breast cancer lead cancer woman Israel 4000 new case every year . Approximately 15-25 % breast cancer human epidermal growth factor receptor 2 ( HER2 ) positive well know HER2 overexpression associate aggressive phenotype poor prognosis resistance certain chemotherapeutic agent . Trastuzumab , anti-HER2 humanize monoclonal antibody , standard treatment early metastatic HER2-positive breast cancer . In addition chemotherapeutic agent , trastuzumab significantly improve response rate survival HER2-positive early metastatic breast cancer . Although well know trastuzumab therapy closely associate symptomatic asymptomatic cardiotoxicity . Addition trastuzumab chemotherapy significantly improve response rate , time disease progression reduction death compare chemotherapy alone HER2-positive metastatic breast cancer ( MBC ) . Thus , anti-HER2 treatment standard therapeutic approach HER2-positive MBC patient visceral crisis . Trastuzumab administration adjuvant metastatic HER2 positive breast cancer associate symptomatic asymptomatic cardiotoxicity . The incidence trastuzumab-mediated cardiotoxicity 27 % antracycline combination 13 % administer paclitaxel . Pertuzumab , recombinant humanize monoclonal antibody bind HER2 dimerization domain , prevents dimerization HER2 HER receptor ( HER3 , HER1 , HER4 ) especially HER3 . Pertuzumab differs trastuzumab epitope binding region light chain ; pertuzumab bind domain 2 ofHER2 essential dimerization , whereas trastuzumab bind domain 4 HER2 . Blocking HER2-HER3 dimerization postulate clinically relevant action pertuzumab effectively block her2-mediated cell signal . Pertuzumab indicate combination trastuzumab docetaxel treatment patient HER2-positive metastatic breast cancer receive prior anti-HER2 therapy chemotherapy metastatic disease . The randomized , double-blind , placebo control , phase III CLEOPATRA ( CLinical Evaluation OfPertuzumab And Trastuzumab ) study involve 808 patient HER2-positive MBC receive prior chemotherapy biologic therapy , randomize placebo plus trastuzumab plus docetaxel pertuzumab plus trastuzumab plus docetaxel first line treatment disease progression . No additional cardiotoxicity observe add pertuzumab compare placebo . The incidence cardiac disorder assess investigator similar placebo ( 16.4 % ) pertuzumab ( 14.5 % ) arm . Left ventricular systolic dysfunction ( LVSD ) observe 8.3 % 4.4 % placebo pertuzumab patient , respectively . Left ventricular systolic dysfunction grade III high report 7 ( 1.8 % ) patient placebo arm 4 ( 1.0 % ) pertuzumab arm . Treatment breast cancer pertuzumab plus trastuzumab plus docetaxel first line treatment disease progression might complicate cardiotoxicity 14.5 % Patients . Cardinale et al show troponin I ( TNI ) positive identifies trastuzumab-treated patient risk cardiotoxicity unlikely recover cardiac dysfunction despite HF therapy . There little data reversibility identification patient risk cardiotoxicity pertuzumab plus trastuzumab plus docetaxel regimen recover cardiac dysfunction , information crucial . The usefulness troponin I ( TNI ) Brain natriuretic peptide ( BNP ) identification patient risk PT cardiotoxicity prediction LVEF recovery never investigate . base background , study aim evaluate cardiotoxicity pertuzumab plus trastuzumab plus docetaxel regimen application troponin I ( TNI ) Brain natriuretic peptide ( BNP ) setting .</detailed_description>
	<mesh_term>Cardiotoxicity</mesh_term>
	<mesh_term>Taxane</mesh_term>
	<mesh_term>Pertuzumab</mesh_term>
	<mesh_term>Trastuzumab</mesh_term>
	<criteria>Metastatic Breast Cancer patient Her2 Positive Disease . No prior treatment LEVF le 50 %</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2014</verification_date>
</DOC>